2026年11月4日星期三
M
Atlante Universale
Notizie flash globali
US experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei AsiaUS experts warm to Japanese nuclear subs as check on China in Asian waters— 日经 Nikkei AsiaDRAM prices double in 2026 as AI focus squeezes PC makers— 日经 Nikkei AsiaJapan weighs standards for self-driving cars without steering wheels— 日经 Nikkei AsiaMitsubishi to sell part of stake in Canada LNG project to Blackstone funds— 日经 Nikkei AsiaJapan's SBI to invest in US digital bank Erebor, eyeing blockchain settlements— 日经 Nikkei AsiaAnthropic seeks to raise up to $3.5bn from Japanese investors in IPO— 日经 Nikkei AsiaJapan can build defense edge on AI, Palantir CEO says— 日经 Nikkei AsiaUS midterms live: Flooding forces polling sites to relocate— 日经 Nikkei Asia

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Fonte Nature 医学研究7 giorni fa
Sintesi del contenuto

Questo sito fornisce solo titoli e indici di riepilogo; il contenuto completo e i diritti d'autore appartengono all'editore originale. Clicca sul link all'articolo originale per leggerlo.

Vai all'articolo originale
Canale di appartenenza
Salute
Regione di appartenenza
Prospettiva globale
Lingua originale
English
Numero di voce
health-a90987bb

Comments 0 comments

No comments yet. Be the first.

Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial · Atlante Universale